Anuncio • Jan 13
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite Index Imago BioSciences, Inc. has been removed from NASDAQ Composite Index Recent Insider Transactions Derivative • Jan 09
Chief Financial Officer exercised options to buy US$1.3m worth of stock. On the 3rd of January, Laura Eichorn exercised options to buy 37k shares at a strike price of around US$4.05, costing a total of US$150k. This transaction amounted to 18% of their direct individual holding at the time of the trade. Since March 2022, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$34m more than they bought, via options and on-market transactions in the last 12 months. Anuncio • Dec 21
Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis Imago BioSciences, Inc. announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF). Ruxolitinib is a kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including the treatment of intermediate or high-risk MF. The Phase 2 open-label study is being conducted at the Department of Medicine, Queen Mary Hospital and the University of Hong Kong and led by Harinder Gill, M.D. It will enroll approximately 20 participants diagnosed with MF who are either JAK inhibitor naïve or refractory to, relapsed or intolerant of ruxolitinib to assess the safety and efficacy of bomedemstat in combination with ruxolitinib. Treatment cycles will last for 28 days, consisting of an oral administration of both bomedemstat and ruxolitinib once daily. Recent Insider Transactions Derivative • Dec 19
CEO & Director notifies of intention to sell stock Hugh Rienhoff intends to sell 473k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of December. If the sale is conducted around the recent share price of US$35.80, it would amount to US$17m. For the year to December 2020, Hugh's total compensation was 8% salary and 92% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2022, Hugh has owned 489.53k shares directly. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months. Anuncio • Dec 13
Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022 Imago BioSciences, Inc. presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in a poster presentation session during the 64thAmerican Society of Hematology Annual Meeting and Exposition (ASH) taking place 10-13 December 2022. A Phase 2 data set with a cut-off date of 29 April 2022 was previously presented at the 30thEuropean Hematology Association Annual Meeting and congress (EHA) in June 2022. Updated Highlights (available data as of 18 October 2022): Of evaluable patients at 24 weeks: 65% (17/26) showed a decrease in Total Symptom Score (TSS). 19% (5/26) showed a = 50% decrease in TSS. 66% (33/50) showed spleen volume reductions from baseline. 28% (14/50) showed a = 20% spleen volume reduction. The majority of patients had a decrease in mutant allele frequencies (MAF) including driver mutations (e.g., JAK2) and high molecular risk (HMR) mutations (e.g., ASXL1). 90% (37/41) of transfusion-independent patients had stable (19/41) or improved (18/41) hemoglobin at Week 12. 85% (50/59) of patients had an improved (19/59) or stable (31/59) bone marrow fibrosis score post-baseline. No new mutations or transformations to acute myeloid leukemia (AML) while on treatment, even in patients with a high-risk of progression. Safety and Tolerability Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 33% (30/90) of patients and led to discontinuation of the study in 1 patient. There were 44 patients who reported a total of 86 serious adverse events (SAEs), 16% of which were deemed drug-related by the investigator. Anuncio • Dec 01
Iimago Biosciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia Imago BioSciences, Inc. announced that the first participant has been dosed in an investigator-sponsored Phase 1 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory acute myeloid leukemia (AML). Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care. The Phase 1 open-label study is being conducted at the University of Miami, led by Terrence J. Bradley, M.D. It will enroll approximately 18 adult participants diagnosed with AML who have failed at least one standard, front-line therapy and will assess the safety and efficacy of bomedemstat in combination with venetoclax (VenBom therapy). This combination regimen consists of once daily, oral administration of both bomedemstat and venetoclax. Participants will receive three cycles of the treatment, and may continue to receive treatment as long as they experience clinical benefit or until disease progression. Anuncio • Nov 23
Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $ billion $1.2 billion. Merck Sharp & Dohme Corp. entered into a definitive agreement to acquire Imago BioSciences, Inc. (NasdaqGS:IMGO) for $1.2 billion on November 19, 2022. Merck & Co will acquire Imago for $36.00 per share in cash. The Offer shall expire at one minute after 11:59 p.m., Eastern time on the date that is 20 Business Days after the commencement of the Offer. Imago will be obligated to pay a termination fee of $47,100,000.00 to Merck in certain customary circumstances. The consummation of the Offer is also conditioned on: (i) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) and (ii) the tender of shares representing at least a majority of the total number of Imago’s outstanding shares, other customary conditions. The Board of Directors of Imago BioSciences has unanimously (i) approved the execution, delivery and performance of the merger agreement and the consummation of the transactions contemplated by the merger agreement, including the Offer and the Merger, and (ii) agreed to recommend that the Imago stockholders accept the Offer and tender their shares of Company common stock pursuant to the Offer, subject to customary exceptions allowing for the exercise of the fiduciary duties of the Board of Directors of the Company under applicable law. The Board of Managers of Merck has approved this agreement. The transaction is expected to close in the first quarter of 2023. Saee Muzumdar of Gibson, Dunn & Crutcher LLP served as legal advisor to Merck. Benjamin A. Potter; Luke J. Bergstrom; Max Schleusener of Latham & Watkins LLP served as legal advisors to Imago. Morgan Stanley & Co. LLC acted as financial advisor to Merck in this transaction. Centerview Partners LLC acted as financial advisor to Imago Price Target Changed • Nov 22
Price target increased to US$35.67 Up from US$33.00, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of US$35.60. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year. Price Target Changed • Nov 16
Price target decreased to US$33.00 Down from US$35.75, the current price target is an average from 5 analysts. New target price is 83% above last closing price of US$18.00. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$1.93 next year compared to a net loss per share of US$2.70 last year. Price Target Changed • Oct 28
Price target decreased to US$33.00 Down from US$35.75, the current price target is an average from 5 analysts. New target price is 95% above last closing price of US$16.95. Stock is down 36% over the past year. The company is forecast to post a net loss per share of US$1.82 next year compared to a net loss per share of US$2.70 last year. Anuncio • Sep 02
Imago BioSciences, Inc. Appoints Hsiangyi Chiang as Principal Accounting Officer On August 29, 2022, the Board of Directors of Imago BioSciences, Inc. (the Company), appointed HsiangyiChiang as the Company's principal accounting officer, effective immediately. Ms. Chiang, age 55, has served as the Company's Senior Vice President, Finance, since January 2022, prior to this Ms. Chiang held the role of Vice President, Finance, from February 2021. Prior to joining the Company, Ms. Chiang served as vice president of finance at Blade Therapeutics, Inc. from 2019, and from 2017 to 2019 as the head of finance and accounting at Medeor Therapeutics, Inc. From 2016 to 2017, Ms. Chiang served as vice president of finance, global controller at Establishment Labs Holdings, Inc., and from 2014 to 2016 as senior director and corporate controller at Principia Biopharma, Inc. Laura Eichorn, the Company's Chief Financial Officer, will no longer serve as the Company's principal accounting officer and will continue to serve as the Company's principal financial officer, effectively immediately. Recent Insider Transactions Derivative • Aug 26
Chief Financial Officer notifies of intention to sell stock Laura Eichorn intends to sell 22k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$18.39, it would amount to US$405k. Since March 2022, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$2.1m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Aug 17
Senior VP of Chemistry exercised options and sold US$204k worth of stock On the 15th of August, Amy Tapper exercised 12k options at a strike price of around US$2.52 and sold these shares for an average price of US$19.18 per share. This trade did not impact their existing holding. Since March 2022, Amy has owned 119.05k shares directly. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months. Anuncio • Jun 11
Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022 Imago BioSciences, Inc. presented updated positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis. The data were presented in a poster session during the 30th European Hematology Association Annual Meeting and Congress (EHA), taking place 9-12 June 2022. Previously, a Phase 2 data set with a cut-off of 31 October 2021 was presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in December 2021. Updated Highlights (as of 29 April 2022 data cutoff): Of the evaluable patients at 24 weeks, 55% (28/51) showed a decrease in Total Symptom Score (TSS), 22% (11/51) showed a =50% decrease in TSS, 64% (32/50) showed spleen volume reductions; 52% (36/69) of patients had a decrease in mutant allele frequencies (MAFs) including driver mutations (e.g., JAK2) with the greater reduction in ASXL1, a high molecular risk (HMR) mutation; 90% (37/41) of transfusion-independent patients had stable or improved hemoglobin at Week 12; 85% (50/59) of patients had an improved (19/59) or stable (31/59) bone marrow fibrosis score post-baseline; No new mutations or transformation to acute myeloid lymphoma (AML) in patients with high risk of progression. Safety & Tolerability: Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis. The most common non-hematologic adverse event (AE) related to bomedemstat was dysgeusia (altered taste), which occurred in 36% of patients and dysgeusia led to discontinuation in 1 patient; There were 14 serious adverse events (SAEs) deemed related to bomedemstat per the Investigator. Details on the Imago EHA Presentation: Poster Presentation Title: A Phase 2 Study of IMG-7289 (Bomedemstat) in Patients With Advanced MyelofibrosisSession: 16. Myeloproliferative neoplasms – Clinical. Presenter: Harinder Gill, M.D., study investigator and presenter of the data, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong KongDate & Time: June 10, 2022, at 10:30 AM ET. Anuncio • May 10
Imago Biosciences, Inc Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer Imago BioSciences, Inc. announced that the first participant has been treated in an investigator-sponsored Phase 1/2 study of bomedemstat in combination with atezolizumab during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer. The study is being conducted in Seattle and led by Rafael Santana-Davila, M.D., associate professor at the University of Washington School of Medicine and Joseph Hiatt, M.D., Ph.D., of Fred Hutchinson Cancer Center (“Fred Hutch”), and in collaboration with the National Cancer Institute funded Fred Hutch Lung Specialized Project of Research Excellence. Bomedemstat is an inhibitor of lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in cell growth. Atezolizumab is an anti-PD-L1 monoclonal antibody medication approved by the U.S. Food and Drug Administration in 2021 as adjuvant treatment for non-small cell lung cancer. The Phase 1/2 open-label study will enroll approximately 34 participants diagnosed with ES-SCLC to establish the safety and tolerability of a combination treatment with bomedemstat and atezolizumab. Treatment cycles will last for 21 days, consisting of an oral administration of bomedemstat once daily and intravenous administration of atezolizumab on day 1. Participants are followed up after 30 days and every 12 weeks thereafter. In ongoing Phase 2 studies in bone marrow cancers, bomedemstat has been generally well-tolerated and has demonstrated significant symptom improvement for patients with essential thrombocythemia and advanced myelofibrosis. Anuncio • May 04
Imago Biosciences Inc. Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia Imago BioSciences, Inc. announced that enrollment has been completed for the Phase 2 clinical study of bomedemstat for the treatment of essential thrombocythemia (ET) with 73 patients enrolled, exceeding the initial target enrollment of 60 patients. This study is designed to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral lysine-specific demethylase 1 (LSD1) inhibitor, in patients with ET who have failed at least one standard therapy. In December 2021, Imago presented a positive data update at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition from the Phase 2 ET clinical study. As a monotherapy in a 2nd line ET population, bomedemstat demonstrated significant and durable hematologic control and symptom improvement while maintaining hemoglobin levels. The data demonstrated that 93% of patients dosed for more than 6 weeks with bomedemstat achieved a reduced platelet count to within the normal range, a primary clinical objective. Based on the ASH data, bomedemstat continued to be generally well-tolerated and demonstrated an encouraging safety profile in ET patients. This Phase 2 multi-center, open-label study is designed to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of bomedemstat, an oral inhibitor of LSD1, an enzyme, that plays a central role in the production of blood cells in the bone marrow (www.clinicaltrials.gov Identifier NCT04254978). Eligible patients aged 18 or older with ET who had failed at least one standard therapy and required treatment in order to lower their platelet count were considered eligible for participation in this study. Study objectives include: safety and tolerability, reduction of platelet count to =400 x 109/L in the absence of thromboembolic events and disease progression, durability of platelet as well as white blood cell (WBC) count reduction and reduction in mutant allele frequency (MAF). The trial is being conducted in the United States, the United Kingdom, Europe, New Zealand, and Australia. Plan to provide interim data at the June EHA meeting and results from the completed study in the second half of the year 2022. Recent Insider Transactions Derivative • Feb 26
COO & Interim CFO exercised options and sold US$153k worth of stock On the 22nd of February, Laura Eichorn exercised 8k options at a strike price of around US$2.52 and sold these shares for an average price of US$21.60 per share. This trade did not impact their existing holding. Since September 2021, Laura has owned 207.74k shares directly. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Feb 04
Senior VP of Chemistry exercised options and sold US$115k worth of stock On the 1st of February, Amy Tapper exercised 7k options at a strike price of around US$2.10 and sold these shares for an average price of US$19.76 per share. This trade did not impact their existing holding. Since September 2021, Amy has owned 119.05k shares directly. Company insiders have collectively sold US$627k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Jan 16
Insider exercised options and sold US$254k worth of stock On the 12th of January, Jennifer Peppe exercised 14k options at a strike price of around US$1.52 and sold these shares for an average price of US$19.68 per share. This trade did not impact their existing holding. Since September 2021, Jennifer has owned 148.81k shares directly. Company insiders have collectively sold US$512k more than they bought, via options and on-market transactions in the last 12 months. Anuncio • Dec 12
Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021 Imago BioSciences, Inc. presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with advanced myelofibrosis (MF). The data were presented in an oral session during the 63rdAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021. Previously, a Phase 2 data set with a cut-off date of May 17, 2021 was presented at the European Hematology Association 2021 Virtual Congress. Updated Highlights (as of November 1, 2021 cutoff): Of the evaluable patients at 24 weeks: 74% (17/23) showed a decrease in Total Symptom Score (TSS). 26% (6/23) showed a =50% decrease in TSS. 75% (30/40) showed spleen volume reductions. 81% (103/127) of mutant allele frequencies (MAFs) were either stable (45%) or reduced (36%), including driver and high molecular risk (HMR) mutations such as ASXL1. 89% (32/36) of patients who were transfusion-independent at baseline had stable or improved hemoglobin at 12 weeks. No new mutations or transformation to acute myeloid lymphoma (AML) in more than 600 days of follow-up in patients with high risk of progression. Safety & Tolerability: Bomedemstat was generally well-tolerated to date in patients with myelofibrosis. The most common non-hematologic AE related to bomedemstat was dysgeusia (altered taste), which occurred in 27 patients (30%). About Imago’s Phase 2 Advanced Myelofibrosis Program: Myelofibrosis (MF) is a progressive cancer in which the bone marrow is gradually replaced by fibrous, scar-like tissue. There is a significant unmet need for a disease-modifying therapy. The need is greatest in patients with MF whose disease is not adequately managed with current JAK inhibitors, the current standard of care. This Phase 2b multi-center, open-label study is designed to assess the safety, efficacy, pharmacodynamics, and spleen volume reduction of bomedemstat, an oral inhibitor of the lysine-specific demethylase 1 (LSD1). Eligible patients aged 18 or over with MF who are refractory or resistant to, intolerant of, are inadequately controlled by or ineligible for approved therapies were considered for the study. Exploratory assessments include symptom reduction, changes in cytokine profiles, changes in the frequency of mutant alleles and bone marrow fibrosis. The trial is being conducted in the United States, United Kingdom, European Union and Hong Kong. This ongoing 24-week study completed enrollment in May 2021 for a total of 89 patients. Executive Departure • Oct 05
Chief Financial Officer Matthew Plunkett has left the company During their tenure, earnings grew by 110% annually compared to the industry average of 4.9%. On the 28th of September, Matthew Plunkett left the company after less than a year in the role. We don't have any record of a personal shareholding under Matthew's name. Matthew is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 9.29 years.